ClinicalTrials.gg
TerminatedNCT04383691Updated Jan 17, 2023

A Study of Lurasidone Compared With Placebo for the Treatment of Bipolar I Depression

A Phase 3 interventional study of Lurasidone HCl and Placebo in Bipolar I Depression, sponsored by Sumitomo Pharma (Suzhou) Co., Ltd.. Terminated at 26 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-01-17.

Sponsored by Sumitomo Pharma (Suzhou) Co., Ltd. (formerly part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment

Why this study was terminated
Company's business decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Depression by Sumitomo Pharma Co., Ltd. — none open to participants now, none under way, none of them phase 3. Depression · Sumitomo Pharma Co., Ltd..

Enrollment
7th of 11
124 · median 211
Started
2020
the only one that year
Phase 3
9 of 11
none open now
Registered
9th of 11
by date

Among the 11 studies in Depression by Sumitomo Pharma Co., Ltd., this one is the 7th largest by enrollment, is the only one that started in 2020, is one of 9 in phase 3, and was the 9th registered.

Depression

8,595 studies on the registry are indexed under Depression; 1,732 are open to participants now.

Browse Depression studies →

Open to participants now

None of the 11 studies in Depression by Sumitomo Pharma Co., Ltd. is open now. The open studies under Depression, anywhere →

Who these studies take

Of the 1,094 Depression studies recruiting now, 472 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 314 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Depression by Sumitomo Pharma Co., Ltd. as a file.
02

Study summary

The study evaluates the efficacy and safety of lurasidone compared with placebo in treating Bipolar I Depression.

Read the detailed description

The primary objective is to compare the efficacy of lurasidone (20-120 mg/day) monotherapy with that of placebo in patients with Bipolar I Depression by assessing the change from baseline in the MADRS total score at Week 6.

03

Conditions studied

  • Bipolar I Depression

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Patients who have provided written voluntary consent in person after receiving and understanding adequate explanation about the study, including the objectives, content, expected therapeutic and pharmacological effects, and risks.
  2. Outpatients who are aged 18 through 65 years at time of .
  3. Patients with bipolar I disorder, most recent episode depressed, without rapid cycling disease course ( no less than 4 episodes of mood disturbance in the 12 months prior to screening), and without psychotic features (diagnosed by criteria).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
124 participants (actual)

Study arms

  • Experimental
    Lurasidone

    Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7. Flexible dosing of study drug will be permitted beginning on Day 8.

    Drug: Lurasidone HCl

  • Placebo comparator
    Placebo

    Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Placebo.

    Drug: Placebo

Interventions

  • Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7. Flexible dosing of study drug will be permitted beginning on Day 8.

  • DrugPlacebo

    Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Placebo.

06

What researchers measure

Primary outcomes

  1. Change from baseline in the MADRS total score at Week 6

    Montgomery-Asberg Depression Rating Scale (MADRS)is a clinician-rated assessment of a subject's level of depression. The MADRS total score ranges from a minimum of 0 to a maximum of 60. For the MADRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome. The MADRS contains ten (10) items. The total score is computed as the sum of the scores for the 10 items.

    Time frame: Baseline/ week 6

Secondary outcomes

  1. Change from baseline in the CGI-BP-S (depression) score at Week 6

    Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) score (depression) is a clinician-rated assessment of a subject's level of depression. The CGI depression score ranges from a minimum of 1 to a maximum of 7. For the CGI depression score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome.

    Time frame: Baseline/ week 6

Other outcomes

  1. Change from baseline in the MADRS total score at each assessment point

    Montgomery-Asberg Depression Rating Scale (MADRS)is a clinician-rated assessment of a subject's level of depression. The MADRS total score ranges from a minimum of 0 to a maximum of 60. For the MADRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome. The MADRS contains ten (10) items. The total score is computed as the sum of the scores for the 10 items.

    Time frame: Baseline/ Week 1/ Week2/ Week3/ Week4/ Week5/ Week 6

  2. Change from baseline in the CGI-BP-S (depression) score at each assessment point

    Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) score (depression) is a clinician-rated assessment of a subject's level of depression. The CGI depression score ranges from a minimum of 1 to a maximum of 7. For the CGI depression score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome.

    Time frame: Baseline/ Week 1/ Week2/ Week3/ Week4/ Week5/ Week 6

  3. Change from baseline in the SDS total score at Week 6

    Sheehan Disability Scale (SDS) total score is a subject-rated assessment of a subject's level of functional impairment in work/school, social life and family life/home responsibilities. The SDS total score ranges from a minimum of 0 to a maximum of 30. For the SDS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome. The SDS contains three (3) items. The total score is computed as the sum of the scores for the 3 items.

    Time frame: Baseline/ week 6

  4. Change from baseline in the YMRS total score at Week 6 and each assessment point

    YMRS (Young Mania Rating Scale) is a clinician-rated assessment of the severity of mania in subjects with a diagnosis of bipolar disorder. The YMRS total score ranges from a minimum of 0 to a maximum of 60. For the YMRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome. The YMRS contains eleven (11) items. The total score is computed as the sum of the scores for the 11 items.

    Time frame: Baseline/ Week 1/ Week2/ Week3/ Week4/ Week5/ Week 6

  5. Change from baseline in the HAM-A total score at Week 6

    The Hamilton Rating Scale for Anxiety (HAM-A) scale is a rating scale developed to quantify the severity of anxiety symptomatology. The HAM-A total score ranges from a minimum of 0 to a maximum of 56. For the HAM-A total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome. The HAM-A contains fourteen (14) items. The total score is computed as the sum of the scores for the 14 items.

    Time frame: Baseline/ week 6

  6. Incidence of Adverse events (AEs) and Adverse drug reactions (ADRs)

    Adverse events, adverse drug reactions

    Time frame: Screening/ Baseline/ Week 1/ Week2/ Week3/ Week4/ Week5/ Week 6/ Follow up

07

Study locations

26 sites
  • Beijing Anding Hospital capital medical university
    Beijing, Beijing 100088, China
  • Beijing HuiLongGuan Hospital
    Beijing, Beijing 100096, China
  • Peking University 6th Hospital
    Beijing, Beijing 100191, China
  • Chongqing Mental Health Center
    Chongqing, Chongqing 400036, China
  • Xiamen Xianyue Hospital
    Xiamen, Fujian 101191, China
  • Guangzhou Huiai Hospital
    Guangzhou, Guangdong 510370, China
  • Shenzhen Kangning Hospital
    Shenzhen, Guang 518118, China
  • Hebei Provincal Mental Health Center
    Baoding, Hebei 0711028, China
  • The 2nd Affiliated Hospital of Xinxiang Medical University
    Xinxiang, Henan 464000, China
  • Zhumadian Psychiatric Hospital
    Zhumadian, Henan 453000, China
  • Wuhan Mental Health Center
    Wuhan, Hubei 430022, China
  • Brain Hospital of Hunan Province
    Changsha, Hunan 410000, China
  • Nanjing Brain Hospital
    Nanjing, Jiangsu 210029, China
  • Ningbo Kangning Hospital
    Ningbo, Jiangsu 315201, China
  • Wuxi Mental Health Center
    Wuxi, Jiangsu 214151, China
  • Zhenjiang mental health center
    Zhenjiang, Jiangsu 212001, China
  • Dalian Seventh People's Hospital
    Dalian, Liaoning 116086, China
  • Jining Psychiatric prevention and treatment hospital
    Jining, Shandong 272000, China
  • Shanghai Mental Health Center
    Shanghai, Shanghai 200030, China
  • Shanghai Tongji Hospital
    Shanghai, Shanghai 200065, China
  • Mental Health Center of Xi'an City
    Xi'an, Shanxi 710061, China
  • The forth People's Hospital of Chengdu
    Chengdu, Sichuan 610036, China
  • Tianjin Anding Hospital
    Tianjin, Tianjin 300074, China
  • Urumqi 4th People's Hospital
    Urumqi, Xinjiang 830002, China
  • The 1st Affiliated Hospital of Xinjiang Medical University
    Urumqi, Xinjiang 830054, China
  • The 1st Hospital of Zhejiang Province
    Hangzhou, Zhejiang 310003, China
08

References and documents

Individual participant data

Plan to share: No — There is no plan to share IPD.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Dec 2022, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2020
First posted
May 12, 2020
StartActual
Dec 11, 2020
Primary completionActual
Dec 23, 2022
CompletionActual
Dec 23, 2022
Last update
Jan 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04383691
Responsible party
Sponsor
First posted
May 12, 2020
Start date
Dec 11, 2020
Primary completion
Dec 23, 2022
Completion
Dec 23, 2022
Last update
Jan 17, 2023

Study contacts

Gang Wang, Doctor
principal investigator · Beijing Anding Hospital capital medical university

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion